577 related articles for article (PubMed ID: 27689326)
1. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
[TBL] [Abstract][Full Text] [Related]
2. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
5. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
6. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
Gao J; Dai C; Yu X; Yin XB; Zhou F
J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
[TBL] [Abstract][Full Text] [Related]
9. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
10. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.
Jin W; Chen L; Cai X; Zhang Y; Zhang J; Ma D; Cai X; Fu T; Yu Z; Yu F; Chen G
Oncol Rep; 2017 Jan; 37(1):273-280. PubMed ID: 27878301
[TBL] [Abstract][Full Text] [Related]
13. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
14. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
[TBL] [Abstract][Full Text] [Related]
15. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
16. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
17. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
18. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z
Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398
[TBL] [Abstract][Full Text] [Related]
19. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.
Li WF; Dai H; Ou Q; Zuo GQ; Liu CA
Tumour Biol; 2016 May; 37(5):5885-95. PubMed ID: 26589417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]